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Traumatic Brain Injury
Anoxic Brain Injury

It is not uncommon for physicians who treat patients with traumatic brain injuries
to see wide fluctuations in the heart rate, respiratory rate and blood pressure. For
decades, these fluctuations were thought to be seizures, caused by pressure on the
thalamus. They were originally termed Diencephalic Autonomic Seizures by Dr. Wilder
Penfield in 1929. He described episodes of lacrimation, hypertension, diaphoresis
and agitation. Dr. Penfield’s “seizures” were later shown to have no electrographic
correlate. Since that time, many names have been used to describe similar episodes:
Dysautonomia, Sympathetic Storming, Brainstem Attacks, Autonomic Dysregulation,
Paroxsymal Autonomic Instability with Dystonia and Paroxysmal Sympathetic Hyperactivity to name only a few.

Ischemic Stroke

Paroxysmal Sympathetic Hyperactivity (PSH) occurs in acquired brain injury and
features simultaneous, paroxysmal transient increases in sympathetic and motor
activity.1 It is most commonly associated with traumatic brain injury. However, it has
been documented in many neurologic conditions (Table 1) and an episode can be
precipitated by a variety of triggers. 2 (Table 2).

Suctioning

Intracranial Hemorrhage
Aneurysmal Subarachnoid Hemorrhage
Brain Tumor
Encephalitis

Table 2. Triggers Precipitating PSH Attack

Turning
Bathing
Physical Exam

One of the difficulties in recognizing PSH is that many of the symptoms are found in
other clinical syndromes. It is a diagnosis of exclusion and the proper workup must be
completed before beginning treatment.3 The clinical features of PSH include tachycardia, tachypnea, hypertension, fever, diaphoresis and dystonic posturing during the
episodes. Table 3 highlights many of the conditions which share similar features to PSH.

PSH has been described as occurring
in three phases.4 The first phase occurs
immediately after the injury. At this
early point in the disease process, there
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Mental
Status

T

HR

RR

BP

Pupil Size Sweating

Agitation

Posturing CPK

↓

↑

↑

↑

↑

↑

+

+

↑

?

Malignant Hyperthermia ↓

↑

↑

↑

±↑

NA

NA

NA

+>-

↑

NMS

↓

↑

Increased ICP

↓

Paroxsymal
Sympathetic
Hyperactivity

↑

↑

↑/↓

NA

+

NA

+

↑

↓

↓

↑

±↑

NA

NA

±

NA

NA

Central Fever

±↓

↑

↑

↑

NA

Infection

±↓

↑

↑

↑

↑/↓

Nonconvulsive
seizures/epilepsy

NA

NA

NA

NA

NA

Narcotic Withdrawal

±↓

NA

↑

↑

Autonomic dysreflexia

NA

↑

↑

↑

NA

NA

NA

NA

±

NA

NA

NA

±↑

NA

±

NA

NA

NA

↑

+

NA

NA

NA

↑

NA

+

NA

NA

NA

Abbreviations: NMS, neuroleptic malignant syndrome; T, temperature; HR, heart rate; RR, respiratory rate; BP, blood pressure; CPK, creatine phosphokinase; up
arrow, increased; down arrow, decreased. Adapted from Blackman et al Archives of Neurology 2004;61:321-328
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Table 4. Severity of Clinical Features Assessment Tool

Table 5. Diagnosis Likelihood Tool (DLT)

Paroxysmal Sympathetic Hyperactivity – Assessment Measure
Clinical Features Scale

Score 1 point for each feature present

Score

1

2

3

Heart Rate

<100

100-119

120-139

≥140

Sympathetic over-reactivity to normally non-painful stimuli

Respiratory
Rate

<18

18-23

24-29

≥30

Features persist ≥3 consecutive days

Systolic Blood <240
Pressure

140-159

160-179

≥180

Temperature

<37

37-37.9

38-38.9

≥39

Sweating

None

Mild

Moderate

Severe

Posturing
during
episodes

None

Mild

Moderate

Severe

Severity of Clinical Features

CFS Total

None

0

Mild

1-6

Moderate

7-12

Severe

≥13

are no specific signs that distinguish
a patient who will go on to develop
PSH from those who don’t. Phase two
begins after the withdrawal of sedation and or paralytics. It is at this point
that patients distinguish themselves
and either develop typical PSH features
(hypertension, hyperthermia, rigidity etc.)
or don’t. The PSH episodes are sporadic
and intense at times and have variable
responses to medical management. The
duration of this phase is unpredictable. It
can last from weeks to months. The third
phase was called PSH “burnt out.” The
patient no longer exhibits all the clinical
features and can be left in a spastic or
dystonic position with varying degrees
of recovery.
In 2014, the Journal of Neurotrauma
published a consensus statement
aimed at formalizing the nomenclature,
including definition and diagnostic
criteria. Tables 4 and 5 detail the diagnostic criteria.
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Episodes are paroxysmal in nature

Features persist ≥ 2 weeks post-brain injury
Features persist despite treatment of alternative differential
diagnoses
Medication administered to decrease sympathetic features
≥ 2 episodes daily
Absence of parasympathetic features during episodes
Absence of other presumed cause of features

CSF
Total

36

Clinical features occur simultaneously

0

Antecedent acquired brain injury

DLT total
Combined Total Points
Clinical Severity Features + Diagnostic Likelihood Tool
PSH Diagnostic
Likelihood

Unlikely < 8
Possible 8-16
Probable > 17

(Adapted from Baguley I. et al. Journal of Neurotrauma 2014;31:1515-1520)

PAROXYSMAL SYMPATHETIC
HYPERACTIVITY –
ASSESSMENT MEASURE
Management of PSH involves both
non-pharmacologic and pharmacologic
treatment. Non-pharmacologic management includes decreasing external
stimuli, limiting visitation, minimizing
exams or noxious stimuli, or grouping
activities (turning, suctioning, bathing).
Pharmacologic management is aimed
at dampening sympathetic outflow or
activating parasympathetic system. Most
commonly used are benzodiazepines,
beta-blockers and opiates. Most medical
treatment involved depressing the CNS
systems and causes increased sedation.5
(Table 6).
Managing the symptoms is important
in preventing secondary brain injury.
Patients who are not treated are at risk
for cerebral edema, intracranial bleeding
from malignant hypertension. There
is a risk of ischemia due to decreased

cerebral oxygenation and neuronal loss
due to prolonged sympathetic activation.
There are other non-brain injury risks
that occur due to prolonged untreated
PSH. These include electrolyte abnormalities, dehydration and kidney injury
from excessive diaphoresis. Cardiac
injury can occur from repetitive significant tachycardia and muscle wasting.
Weight loss and malnutrition can occur
from increased metabolic demands.
Lastly, it is critical that physicians discuss
PSH with the families, as these episodes
can be very upsetting and distressful to
witness. Explaining what is happening to
the patient and how it is being managed
can help alleviate this stress. It is also a
way to involve the family in monitoring
for triggers and timing of episodes.
Developing a bedside chart which details
triggers, timing, duration of episodes,
medications administered and response
to treatment is useful in the long-term
management.

Paroxysmal Sympathetic Hyperactivity

Table 6.

First Line

Symptom

Receptor Agonist or
Antagonist

Medication

Additional

Tachycardia

β2-Adrenergic blocker

Propranolol

– Dampens sympathetic activity; decreases serum catecholamines, reduces cardiac workload
– Dosing limited by HR and BP
– Caution in asthmatics

First Line

Hyperthermia

COX-2 inhibitor

Acetaminophen

– Dosing max 4gm/daily

(Po 650-975mg q6hr)
(IV 1gm q6h)
First Line
First Line

First Line

Second Line

Diaphoresis &
hyperthermia

Dopamine agonist

Tachypnea

GABA-A Antagonist

Pain

Hyperthermia

Opiate Agonist

Dopamine D2 Antagonist

Bromocriptine

– Acts at the hypothalamic level.

(2.5-5mg q8hr)

– Can increase up to 30-40mg/day

Diazepam

– No max dose

(po 5mg q8 hr and titrate
up)

– Dosing limited based on sedation

Morphine Sulfate

– Start low and titrate to effect

Fentanyl

– Dosing varies by agent

Oxycodone

– High abuse potential long term

Chlorpromazine

– Acts along the hypothalamus
– Good for recurrent hyperthemia
– Should not be used long term
– Risk of extra-pyramidal effects & liver failure

Second line

Dystonia

GABA-B agonist

Baclofen

– Low potential for abuse
– L ong term use requires slow wean to avoid withdrawal/
seizures

Second Line

Dystonia

Post-synaptic muscle
relaxant, Inhibits Ca+
release intracellularly

Dantrolene

–C
 aution if other Ca+ Channel Blockers on board can cause
hyperkalemia and
– Caution if liver disease

Second Line

Tachycardia

α2 Agonist

Clonidine

– Lowers levels of norepinephrine

Second Line

Tachyacrdia

β1, β2, α1 antagonist

Labetalol

– Dosing limited by HR and BP

Onset time

Trigger

HR
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